Cerapedics Partners with Vizient to Enhance Accessibility of Innovative Bone Graft Product
Cerapedics Partnerships and Innovations in Orthopedics
Cerapedics Inc., a leading name in orthopedic advancements, has made a significant move by entering into a supplier agreement with Vizient, a healthcare performance improvement firm. This collaboration focuses on the PearlMatrix® P-15 Peptide Enhanced Bone Graft, which is specifically designed for spinal fusion procedures in patients suffering from degenerative disc disease.
The agreement promises to provide enhanced access to PearlMatrix, a groundbreaking product that accelerates bone growth and facilitates quicker spinal fusion. This contract is particularly beneficial for a diverse demographic of healthcare providers, including academic medical centers and community hospitals, which are under Vizient's umbrella. Cerapedics' innovative product not only supports better patient outcomes but also offers cost-effective solutions that can ease the financial burden on healthcare facilities.
About PearlMatrix
PearlMatrix stands out as the first and only FDA-approved drug-device combination to serve as a bone growth accelerator for a range of surgical approaches, including anterior lumbar interbody fusion (ALIF) and posterior lumbar interbody fusion (PLIF). It is endorsed for its efficacy in boosting lumbar fusion rates, backed by studies that show its effectiveness among patients considered high-risk, including those with type 2 diabetes or those who smoke.
Harnessing the power of the P-15 Osteogenic Cell Binding Peptide, PearlMatrix not only promotes new bone formation but does so significantly faster when compared to traditional methods. This peptide is strategically bound to calcium phosphate particles, ensuring optimal conditions for osteogenic cell attachment. The incorporation of this advanced technology into spinal surgeries signifies a major leap toward improved surgical outcomes, particularly in complex and high-risk patient populations.
The highly anticipated results from the ASPIRE TLIF Investigational Device Exemption (IDE) study demonstrate that patients treated with PearlMatrix exhibited over twice the fusion rate at six months compared to those receiving local autografts. Such promising data underscores the critical impact of this product on patient recovery and overall health outcomes.
Cerapedics’ Vision for Growth
Valeska Schroeder, CEO of Cerapedics, elaborated on this partnership, noting that the agreement with Vizient is a testament to their commitment to advancing patient care while optimizing healthcare economics. This collaboration further expands Cerapedics' reach within its drug-device portfolio, which also includes the i-FACTOR® Bone Graft used for cervical spine procedures.
Cerapedics is steadfast in its dedication to redefine orthopedic solutions, focusing on faster healing times and improved recovery rates. With its headquarters in Westminster, Colorado, Cerapedics continues to make strides in the medical field, ensuring that surgeons have access to innovative tools that improve surgical practices and enhance patient care.
A Step Forward in Orthopedic Care
Conclusion
In conclusion, the alliance between Cerapedics and Vizient reflects a strategic move to deliver high-quality orthopedic products that cater to the evolving needs of patients and healthcare providers alike. As the industry advances, such collaborations are essential for fostering innovation and supporting healthcare facilities in delivering the best possible outcomes for their patients. The potential of products like PearlMatrix to reshape the landscape of spinal surgery cannot be overstated, and Cerapedics is poised to lead that transformation.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.